Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hikma Pharmaceuticals Plc ADR
(OP:
HKMPY
)
53.17
UNCHANGED
Last Price
Updated: 2:41 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
36
Open
53.17
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
53.17
Today's Range
53.17 - 53.17
52wk Range
42.23 - 55.56
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Today 9:46 EDT
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.
Via
Benzinga
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
Performance
YTD
+17.05%
+17.05%
1 Month
+11.15%
+11.15%
3 Month
+6.13%
+6.13%
6 Month
+10.78%
+10.78%
1 Year
+0.14%
+0.14%
More News
Read More
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 08, 2024
From
Guardant Health, Inc.
Via
Business Wire
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
June 12, 2023
Via
Benzinga
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
December 26, 2022
From
Junshi Biosciences
Via
GlobeNewswire
Friday Markets News
March 25, 2022
Via
Talk Markets
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
August 27, 2021
From
Bio-Thera Solutions, Ltd.
Via
Business Wire
Summer Friday
June 25, 2021
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.